Holdco Nuvo Group D.G Ltd. Ordinary Shares
Holdco Nuvo Group D.G Ltd. Ordinary Shares (NUVO) Stock Competitors & Peer Comparison
See (NUVO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUVO | $0.17 | +0.00% | 5.7M | -0.17 | -$1.01 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $87.01 | +0.82% | 151.6B | 24.38 | $3.57 | +2.79% |
| SYK | $294.23 | +0.65% | 112.7B | 35.07 | $8.39 | +1.16% |
| MDT | $77.96 | +0.46% | 100.1B | 21.77 | $3.58 | +3.65% |
| BSX | $56.58 | +1.04% | 84.1B | 23.67 | $2.39 | N/A |
| BRKRP | $337.61 | +2.19% | 51.7B | N/A | N/A | +0.45% |
| EW | $82.76 | -0.53% | 47.7B | 44.74 | $1.85 | N/A |
| PHG | $27.16 | -0.26% | 25.8B | 23.21 | $1.17 | +3.54% |
| DXCM | $60.91 | +0.91% | 23.5B | 26.14 | $2.33 | N/A |
Stock Comparison
NUVO vs BSX-PA Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NUVO is priced at $0.17, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NUVO's ROE is -0.37%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NUVO is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BSX-PA's competition here
NUVO vs ABT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ABT has a market cap of 151.6B. Regarding current trading prices, NUVO is priced at $0.17, while ABT trades at $87.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ABT's P/E ratio is 24.38. In terms of profitability, NUVO's ROE is -0.37%, compared to ABT's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ABT's competition here
NUVO vs SYK Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SYK has a market cap of 112.7B. Regarding current trading prices, NUVO is priced at $0.17, while SYK trades at $294.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SYK's P/E ratio is 35.07. In terms of profitability, NUVO's ROE is -0.37%, compared to SYK's ROE of +0.15%. Regarding short-term risk, NUVO is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SYK's competition here
NUVO vs MDT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MDT has a market cap of 100.1B. Regarding current trading prices, NUVO is priced at $0.17, while MDT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MDT's P/E ratio is 21.77. In terms of profitability, NUVO's ROE is -0.37%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NUVO is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check MDT's competition here
NUVO vs BSX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BSX has a market cap of 84.1B. Regarding current trading prices, NUVO is priced at $0.17, while BSX trades at $56.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BSX's P/E ratio is 23.67. In terms of profitability, NUVO's ROE is -0.37%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NUVO is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BSX's competition here
NUVO vs BRKRP Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BRKRP has a market cap of 51.7B. Regarding current trading prices, NUVO is priced at $0.17, while BRKRP trades at $337.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BRKRP's P/E ratio is N/A. In terms of profitability, NUVO's ROE is -0.37%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, NUVO is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BRKRP's competition here
NUVO vs EW Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, EW has a market cap of 47.7B. Regarding current trading prices, NUVO is priced at $0.17, while EW trades at $82.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas EW's P/E ratio is 44.74. In terms of profitability, NUVO's ROE is -0.37%, compared to EW's ROE of +0.11%. Regarding short-term risk, NUVO is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check EW's competition here
NUVO vs PHG Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PHG has a market cap of 25.8B. Regarding current trading prices, NUVO is priced at $0.17, while PHG trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PHG's P/E ratio is 23.21. In terms of profitability, NUVO's ROE is -0.37%, compared to PHG's ROE of +0.08%. Regarding short-term risk, NUVO is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PHG's competition here
NUVO vs DXCM Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, DXCM has a market cap of 23.5B. Regarding current trading prices, NUVO is priced at $0.17, while DXCM trades at $60.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas DXCM's P/E ratio is 26.14. In terms of profitability, NUVO's ROE is -0.37%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, NUVO is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check DXCM's competition here
NUVO vs STE Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, STE has a market cap of 21B. Regarding current trading prices, NUVO is priced at $0.17, while STE trades at $213.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas STE's P/E ratio is 30.15. In terms of profitability, NUVO's ROE is -0.37%, compared to STE's ROE of +0.10%. Regarding short-term risk, NUVO is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check STE's competition here
NUVO vs ABMD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NUVO is priced at $0.17, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NUVO's ROE is -0.37%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NUVO is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ABMD's competition here
NUVO vs ZBH Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ZBH has a market cap of 16.1B. Regarding current trading prices, NUVO is priced at $0.17, while ZBH trades at $83.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ZBH's P/E ratio is 21.66. In terms of profitability, NUVO's ROE is -0.37%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NUVO is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ZBH's competition here
NUVO vs SNN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SNN has a market cap of 12.8B. Regarding current trading prices, NUVO is priced at $0.17, while SNN trades at $30.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SNN's P/E ratio is 21.02. In terms of profitability, NUVO's ROE is -0.37%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SNN's competition here
NUVO vs PEN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, NUVO is priced at $0.17, while PEN trades at $324.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PEN's P/E ratio is 71.66. In terms of profitability, NUVO's ROE is -0.37%, compared to PEN's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PEN's competition here
NUVO vs SWAV Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NUVO is priced at $0.17, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NUVO's ROE is -0.37%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NUVO is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SWAV's competition here
NUVO vs ALGN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, NUVO is priced at $0.17, while ALGN trades at $168.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ALGN's P/E ratio is 28.25. In terms of profitability, NUVO's ROE is -0.37%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NUVO is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ALGN's competition here
NUVO vs GMED Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, GMED has a market cap of 11.5B. Regarding current trading prices, NUVO is priced at $0.17, while GMED trades at $85.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas GMED's P/E ratio is 21.70. In terms of profitability, NUVO's ROE is -0.37%, compared to GMED's ROE of +0.12%. Regarding short-term risk, NUVO is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check GMED's competition here
NUVO vs PODD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PODD has a market cap of 11.1B. Regarding current trading prices, NUVO is priced at $0.17, while PODD trades at $160.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PODD's P/E ratio is 37.48. In terms of profitability, NUVO's ROE is -0.37%, compared to PODD's ROE of +0.21%. Regarding short-term risk, NUVO is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PODD's competition here
NUVO vs GKOS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, GKOS has a market cap of 7.9B. Regarding current trading prices, NUVO is priced at $0.17, while GKOS trades at $134.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas GKOS's P/E ratio is -40.65. In terms of profitability, NUVO's ROE is -0.37%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, NUVO is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check GKOS's competition here
NUVO vs BIO-B Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BIO-B has a market cap of 7.1B. Regarding current trading prices, NUVO is priced at $0.17, while BIO-B trades at $261.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BIO-B's P/E ratio is 43.47. In terms of profitability, NUVO's ROE is -0.37%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, NUVO is less volatile compared to BIO-B. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BIO-B's competition here
NUVO vs BIO Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BIO has a market cap of 7B. Regarding current trading prices, NUVO is priced at $0.17, while BIO trades at $257.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BIO's P/E ratio is 42.91. In terms of profitability, NUVO's ROE is -0.37%, compared to BIO's ROE of +0.02%. Regarding short-term risk, NUVO is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BIO's competition here
NUVO vs BRKR Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BRKR has a market cap of 6.7B. Regarding current trading prices, NUVO is priced at $0.17, while BRKR trades at $43.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BRKR's P/E ratio is -182.21. In terms of profitability, NUVO's ROE is -0.37%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, NUVO is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BRKR's competition here
NUVO vs NARI Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NUVO is priced at $0.17, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NARI's P/E ratio is -59.24. In terms of profitability, NUVO's ROE is -0.37%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NUVO is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NARI's competition here
NUVO vs IRTC Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, NUVO is priced at $0.17, while IRTC trades at $124.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas IRTC's P/E ratio is -146.91. In terms of profitability, NUVO's ROE is -0.37%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, NUVO is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check IRTC's competition here
NUVO vs LIVN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, LIVN has a market cap of 3.9B. Regarding current trading prices, NUVO is priced at $0.17, while LIVN trades at $70.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas LIVN's P/E ratio is -15.94. In terms of profitability, NUVO's ROE is -0.37%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, NUVO is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check LIVN's competition here
NUVO vs AXNX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NUVO is priced at $0.17, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NUVO's ROE is -0.37%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NUVO and AXNX have similar daily volatility (0.00).Check AXNX's competition here
NUVO vs ITGR Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, NUVO is priced at $0.17, while ITGR trades at $87.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ITGR's P/E ratio is 21.83. In terms of profitability, NUVO's ROE is -0.37%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, NUVO is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ITGR's competition here
NUVO vs TMDX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, NUVO is priced at $0.17, while TMDX trades at $72.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TMDX's P/E ratio is 16.65. In terms of profitability, NUVO's ROE is -0.37%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, NUVO is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TMDX's competition here
NUVO vs AXGN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, NUVO is priced at $0.17, while AXGN trades at $43.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AXGN's P/E ratio is -68.90. In terms of profitability, NUVO's ROE is -0.37%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, NUVO is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AXGN's competition here
NUVO vs ESTA Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, NUVO is priced at $0.17, while ESTA trades at $72.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ESTA's P/E ratio is -49.00. In terms of profitability, NUVO's ROE is -0.37%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, NUVO is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ESTA's competition here
NUVO vs NUVA Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NUVO is priced at $0.17, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NUVO's ROE is -0.37%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NUVO is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NUVA's competition here
NUVO vs AORT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, NUVO is priced at $0.17, while AORT trades at $35.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AORT's P/E ratio is 168.52. In terms of profitability, NUVO's ROE is -0.37%, compared to AORT's ROE of +0.02%. Regarding short-term risk, NUVO is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AORT's competition here
NUVO vs UFPT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, NUVO is priced at $0.17, while UFPT trades at $221.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas UFPT's P/E ratio is 25.24. In terms of profitability, NUVO's ROE is -0.37%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NUVO is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check UFPT's competition here
NUVO vs AHCO Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AHCO has a market cap of 1.6B. Regarding current trading prices, NUVO is priced at $0.17, while AHCO trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AHCO's P/E ratio is -19.88. In terms of profitability, NUVO's ROE is -0.37%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, NUVO is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AHCO's competition here
NUVO vs PRCT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, NUVO is priced at $0.17, while PRCT trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PRCT's P/E ratio is -13.90. In terms of profitability, NUVO's ROE is -0.37%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NUVO is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PRCT's competition here
NUVO vs INSP Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, NUVO is priced at $0.17, while INSP trades at $45.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas INSP's P/E ratio is 10.36. In terms of profitability, NUVO's ROE is -0.37%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NUVO is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check INSP's competition here
NUVO vs HSKA Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NUVO is priced at $0.17, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NUVO's ROE is -0.37%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NUVO and HSKA have similar daily volatility (0.00).Check HSKA's competition here
NUVO vs TNDM Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, NUVO is priced at $0.17, while TNDM trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TNDM's P/E ratio is -6.08. In terms of profitability, NUVO's ROE is -0.37%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, NUVO is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TNDM's competition here
NUVO vs ATEC Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, NUVO is priced at $0.17, while ATEC trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ATEC's P/E ratio is -8.07. In terms of profitability, NUVO's ROE is -0.37%, compared to ATEC's ROE of -1.42%. Regarding short-term risk, NUVO is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ATEC's competition here
NUVO vs AVNS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NUVO is priced at $0.17, while AVNS trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AVNS's P/E ratio is -15.78. In terms of profitability, NUVO's ROE is -0.37%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NUVO is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AVNS's competition here
NUVO vs CNMD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while CNMD trades at $38.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CNMD's P/E ratio is 21.52. In terms of profitability, NUVO's ROE is -0.37%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, NUVO is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CNMD's competition here
NUVO vs SILK Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SILK's P/E ratio is -18.96. In terms of profitability, NUVO's ROE is -0.37%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NUVO is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SILK's competition here
NUVO vs BFLY Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while BFLY trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BFLY's P/E ratio is -14.13. In terms of profitability, NUVO's ROE is -0.37%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, NUVO is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BFLY's competition here
NUVO vs IRMD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while IRMD trades at $86.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas IRMD's P/E ratio is 47.40. In terms of profitability, NUVO's ROE is -0.37%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NUVO is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check IRMD's competition here
NUVO vs FNA Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas FNA's P/E ratio is -19.83. In terms of profitability, NUVO's ROE is -0.37%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NUVO is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check FNA's competition here
NUVO vs IART Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, NUVO is priced at $0.17, while IART trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas IART's P/E ratio is -2.10. In terms of profitability, NUVO's ROE is -0.37%, compared to IART's ROE of -0.48%. Regarding short-term risk, NUVO is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check IART's competition here
NUVO vs LMRI Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, LMRI has a market cap of 984.2M. Regarding current trading prices, NUVO is priced at $0.17, while LMRI trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas LMRI's P/E ratio is -15.52. In terms of profitability, NUVO's ROE is -0.37%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, NUVO is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check LMRI's competition here
NUVO vs INMD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, INMD has a market cap of 882M. Regarding current trading prices, NUVO is priced at $0.17, while INMD trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas INMD's P/E ratio is 10.31. In terms of profitability, NUVO's ROE is -0.37%, compared to INMD's ROE of +0.13%. Regarding short-term risk, NUVO is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check INMD's competition here
NUVO vs CSII Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NUVO is priced at $0.17, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CSII's P/E ratio is -20.83. In terms of profitability, NUVO's ROE is -0.37%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NUVO is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CSII's competition here
NUVO vs SSII Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SSII has a market cap of 786.5M. Regarding current trading prices, NUVO is priced at $0.17, while SSII trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SSII's P/E ratio is -65.50. In terms of profitability, NUVO's ROE is -0.37%, compared to SSII's ROE of -0.30%. Regarding short-term risk, NUVO is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SSII's competition here
NUVO vs CBLL Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CBLL has a market cap of 771.8M. Regarding current trading prices, NUVO is priced at $0.17, while CBLL trades at $20.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CBLL's P/E ratio is -13.96. In terms of profitability, NUVO's ROE is -0.37%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, NUVO is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CBLL's competition here
NUVO vs CRY Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NUVO is priced at $0.17, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CRY's P/E ratio is 425.71. In terms of profitability, NUVO's ROE is -0.37%, compared to CRY's ROE of +0.02%. Regarding short-term risk, NUVO is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CRY's competition here
NUVO vs BVS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BVS has a market cap of 720.3M. Regarding current trading prices, NUVO is priced at $0.17, while BVS trades at $10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BVS's P/E ratio is 25.98. In terms of profitability, NUVO's ROE is -0.37%, compared to BVS's ROE of +0.16%. Regarding short-term risk, NUVO is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BVS's competition here
NUVO vs BWAY Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BWAY has a market cap of 655.4M. Regarding current trading prices, NUVO is priced at $0.17, while BWAY trades at $16.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BWAY's P/E ratio is 92.83. In terms of profitability, NUVO's ROE is -0.37%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, NUVO is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BWAY's competition here
NUVO vs NPCE Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NPCE has a market cap of 654.9M. Regarding current trading prices, NUVO is priced at $0.17, while NPCE trades at $19.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NPCE's P/E ratio is -29.23. In terms of profitability, NUVO's ROE is -0.37%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, NUVO is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NPCE's competition here
NUVO vs CTKB Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CTKB has a market cap of 632.5M. Regarding current trading prices, NUVO is priced at $0.17, while CTKB trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CTKB's P/E ratio is -9.46. In terms of profitability, NUVO's ROE is -0.37%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, NUVO is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CTKB's competition here
NUVO vs SRDX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NUVO is priced at $0.17, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NUVO's ROE is -0.37%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, NUVO and SRDX have similar daily volatility (0.00).Check SRDX's competition here
NUVO vs TCMD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TCMD has a market cap of 586.7M. Regarding current trading prices, NUVO is priced at $0.17, while TCMD trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TCMD's P/E ratio is 29.90. In terms of profitability, NUVO's ROE is -0.37%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, NUVO is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TCMD's competition here
NUVO vs APEN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NUVO is priced at $0.17, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas APEN's P/E ratio is -9.43. In terms of profitability, NUVO's ROE is -0.37%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NUVO is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check APEN's competition here
NUVO vs SIBN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SIBN has a market cap of 573M. Regarding current trading prices, NUVO is priced at $0.17, while SIBN trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SIBN's P/E ratio is -29.43. In terms of profitability, NUVO's ROE is -0.37%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, NUVO is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SIBN's competition here
NUVO vs ZIMV Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NUVO is priced at $0.17, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NUVO's ROE is -0.37%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, NUVO and ZIMV have similar daily volatility (0.00).Check ZIMV's competition here
NUVO vs CERS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CERS has a market cap of 523M. Regarding current trading prices, NUVO is priced at $0.17, while CERS trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CERS's P/E ratio is -52.20. In terms of profitability, NUVO's ROE is -0.37%, compared to CERS's ROE of -0.15%. Regarding short-term risk, NUVO is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CERS's competition here
NUVO vs PACB Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PACB has a market cap of 498.3M. Regarding current trading prices, NUVO is priced at $0.17, while PACB trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PACB's P/E ratio is -0.91. In terms of profitability, NUVO's ROE is -0.37%, compared to PACB's ROE of -11.23%. Regarding short-term risk, NUVO is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PACB's competition here
NUVO vs VREX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, VREX has a market cap of 495.9M. Regarding current trading prices, NUVO is priced at $0.17, while VREX trades at $11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas VREX's P/E ratio is -7.21. In terms of profitability, NUVO's ROE is -0.37%, compared to VREX's ROE of -0.14%. Regarding short-term risk, NUVO is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check VREX's competition here
NUVO vs OFIX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, OFIX has a market cap of 487.9M. Regarding current trading prices, NUVO is priced at $0.17, while OFIX trades at $12.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas OFIX's P/E ratio is -8.05. In terms of profitability, NUVO's ROE is -0.37%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, NUVO is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check OFIX's competition here
NUVO vs KIDS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, KIDS has a market cap of 451.3M. Regarding current trading prices, NUVO is priced at $0.17, while KIDS trades at $17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas KIDS's P/E ratio is -10.46. In terms of profitability, NUVO's ROE is -0.37%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NUVO is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check KIDS's competition here
NUVO vs DCTH Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, DCTH has a market cap of 390.5M. Regarding current trading prices, NUVO is priced at $0.17, while DCTH trades at $11.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas DCTH's P/E ratio is 160.57. In terms of profitability, NUVO's ROE is -0.37%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, NUVO is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check DCTH's competition here
NUVO vs LAB Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, LAB has a market cap of 390.4M. Regarding current trading prices, NUVO is priced at $0.17, while LAB trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas LAB's P/E ratio is -8.33. In terms of profitability, NUVO's ROE is -0.37%, compared to LAB's ROE of +0.17%. Regarding short-term risk, NUVO is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check LAB's competition here
NUVO vs VMD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, VMD has a market cap of 353.1M. Regarding current trading prices, NUVO is priced at $0.17, while VMD trades at $9.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas VMD's P/E ratio is 24.89. In terms of profitability, NUVO's ROE is -0.37%, compared to VMD's ROE of +0.11%. Regarding short-term risk, NUVO is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check VMD's competition here
NUVO vs CLPT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CLPT has a market cap of 350.2M. Regarding current trading prices, NUVO is priced at $0.17, while CLPT trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CLPT's P/E ratio is -13.27. In terms of profitability, NUVO's ROE is -0.37%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, NUVO is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CLPT's competition here
NUVO vs PMI Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PMI has a market cap of 347.1M. Regarding current trading prices, NUVO is priced at $0.17, while PMI trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PMI's P/E ratio is -0.30. In terms of profitability, NUVO's ROE is -0.37%, compared to PMI's ROE of +2.17%. Regarding short-term risk, NUVO is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PMI's competition here
NUVO vs SMLR Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NUVO is priced at $0.17, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NUVO's ROE is -0.37%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, NUVO and SMLR have similar daily volatility (0.00).Check SMLR's competition here
NUVO vs MASS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MASS has a market cap of 302M. Regarding current trading prices, NUVO is priced at $0.17, while MASS trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MASS's P/E ratio is -8.33. In terms of profitability, NUVO's ROE is -0.37%, compared to MASS's ROE of -0.26%. Regarding short-term risk, NUVO is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check MASS's competition here
NUVO vs SGHT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SGHT has a market cap of 285.7M. Regarding current trading prices, NUVO is priced at $0.17, while SGHT trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SGHT's P/E ratio is -7.15. In terms of profitability, NUVO's ROE is -0.37%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, NUVO is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SGHT's competition here
NUVO vs CATX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CATX has a market cap of 265.6M. Regarding current trading prices, NUVO is priced at $0.17, while CATX trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CATX's P/E ratio is -2.56. In terms of profitability, NUVO's ROE is -0.37%, compared to CATX's ROE of -0.41%. Regarding short-term risk, NUVO is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CATX's competition here
NUVO vs MGRM Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NUVO is priced at $0.17, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MGRM's P/E ratio is -11.11. In terms of profitability, NUVO's ROE is -0.37%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, NUVO and MGRM have similar daily volatility (0.00).Check MGRM's competition here
NUVO vs AVR Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, AVR has a market cap of 239.5M. Regarding current trading prices, NUVO is priced at $0.17, while AVR trades at $6.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas AVR's P/E ratio is -2.55. In terms of profitability, NUVO's ROE is -0.37%, compared to AVR's ROE of -5.28%. Regarding short-term risk, NUVO is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check AVR's competition here
NUVO vs RXST Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, RXST has a market cap of 239.3M. Regarding current trading prices, NUVO is priced at $0.17, while RXST trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas RXST's P/E ratio is -6.11. In terms of profitability, NUVO's ROE is -0.37%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NUVO is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check RXST's competition here
NUVO vs NVRO Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NUVO is priced at $0.17, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NUVO's ROE is -0.37%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NUVO is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NVRO's competition here
NUVO vs SENS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SENS has a market cap of 223.9M. Regarding current trading prices, NUVO is priced at $0.17, while SENS trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SENS's P/E ratio is -3.23. In terms of profitability, NUVO's ROE is -0.37%, compared to SENS's ROE of -1.04%. Regarding short-term risk, NUVO is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SENS's competition here
NUVO vs ELMD Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ELMD has a market cap of 222.5M. Regarding current trading prices, NUVO is priced at $0.17, while ELMD trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ELMD's P/E ratio is 26.11. In terms of profitability, NUVO's ROE is -0.37%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, NUVO is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ELMD's competition here
NUVO vs PROF Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, PROF has a market cap of 216.7M. Regarding current trading prices, NUVO is priced at $0.17, while PROF trades at $7.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas PROF's P/E ratio is -5.08. In terms of profitability, NUVO's ROE is -0.37%, compared to PROF's ROE of -0.80%. Regarding short-term risk, NUVO is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check PROF's competition here
NUVO vs EYES Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NUVO is priced at $0.17, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas EYES's P/E ratio is N/A. In terms of profitability, NUVO's ROE is -0.37%, compared to EYES's ROE of -3.17%. Regarding short-term risk, NUVO is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check EYES's competition here
NUVO vs ANIK Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, ANIK has a market cap of 201.4M. Regarding current trading prices, NUVO is priced at $0.17, while ANIK trades at $15.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas ANIK's P/E ratio is -19.16. In terms of profitability, NUVO's ROE is -0.37%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, NUVO is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check ANIK's competition here
NUVO vs INGN Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, INGN has a market cap of 196.5M. Regarding current trading prices, NUVO is priced at $0.17, while INGN trades at $7.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas INGN's P/E ratio is -8.36. In terms of profitability, NUVO's ROE is -0.37%, compared to INGN's ROE of -0.12%. Regarding short-term risk, NUVO is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check INGN's competition here
NUVO vs QTI Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, QTI has a market cap of 192.7M. Regarding current trading prices, NUVO is priced at $0.17, while QTI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas QTI's P/E ratio is -3.53. In terms of profitability, NUVO's ROE is -0.37%, compared to QTI's ROE of +3.64%. Regarding short-term risk, NUVO is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check QTI's competition here
NUVO vs CVRX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, CVRX has a market cap of 192.6M. Regarding current trading prices, NUVO is priced at $0.17, while CVRX trades at $7.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas CVRX's P/E ratio is -3.59. In terms of profitability, NUVO's ROE is -0.37%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, NUVO is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check CVRX's competition here
NUVO vs BSGM Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NUVO is priced at $0.17, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NUVO's ROE is -0.37%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, NUVO is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check BSGM's competition here
NUVO vs MDGS Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NUVO is priced at $0.17, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NUVO's ROE is -0.37%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NUVO is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check MDGS's competition here
NUVO vs TLSI Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TLSI has a market cap of 169.1M. Regarding current trading prices, NUVO is priced at $0.17, while TLSI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TLSI's P/E ratio is -2.42. In terms of profitability, NUVO's ROE is -0.37%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, NUVO is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TLSI's competition here
NUVO vs QIPT Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NUVO is priced at $0.17, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NUVO's ROE is -0.37%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NUVO and QIPT have similar daily volatility (0.00).Check QIPT's competition here
NUVO vs EDAP Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, EDAP has a market cap of 155.9M. Regarding current trading prices, NUVO is priced at $0.17, while EDAP trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas EDAP's P/E ratio is -5.33. In terms of profitability, NUVO's ROE is -0.37%, compared to EDAP's ROE of -0.65%. Regarding short-term risk, NUVO is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check EDAP's competition here
NUVO vs APYX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, APYX has a market cap of 148.9M. Regarding current trading prices, NUVO is priced at $0.17, while APYX trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas APYX's P/E ratio is -13.19. In terms of profitability, NUVO's ROE is -0.37%, compared to APYX's ROE of -0.91%. Regarding short-term risk, NUVO is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check APYX's competition here
NUVO vs SNWV Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, SNWV has a market cap of 143.4M. Regarding current trading prices, NUVO is priced at $0.17, while SNWV trades at $16.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas SNWV's P/E ratio is 40.68. In terms of profitability, NUVO's ROE is -0.37%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, NUVO is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check SNWV's competition here
NUVO vs HYPR Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, HYPR has a market cap of 137.3M. Regarding current trading prices, NUVO is priced at $0.17, while HYPR trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas HYPR's P/E ratio is -3.91. In terms of profitability, NUVO's ROE is -0.37%, compared to HYPR's ROE of -0.97%. Regarding short-term risk, NUVO is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check HYPR's competition here
NUVO vs QTRX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, QTRX has a market cap of 129.1M. Regarding current trading prices, NUVO is priced at $0.17, while QTRX trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas QTRX's P/E ratio is -1.10. In terms of profitability, NUVO's ROE is -0.37%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, NUVO is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check QTRX's competition here
NUVO vs TMCI Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, TMCI has a market cap of 124.4M. Regarding current trading prices, NUVO is priced at $0.17, while TMCI trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas TMCI's P/E ratio is -2.06. In terms of profitability, NUVO's ROE is -0.37%, compared to TMCI's ROE of -0.62%. Regarding short-term risk, NUVO is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check TMCI's competition here
NUVO vs NNOX Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, NNOX has a market cap of 122.5M. Regarding current trading prices, NUVO is priced at $0.17, while NNOX trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas NNOX's P/E ratio is -1.52. In terms of profitability, NUVO's ROE is -0.37%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, NUVO is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check NNOX's competition here
NUVO vs RPID Comparison May 2026
NUVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVO stands at 5.7M. In comparison, RPID has a market cap of 117.2M. Regarding current trading prices, NUVO is priced at $0.17, while RPID trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVO currently has a P/E ratio of -0.17, whereas RPID's P/E ratio is -2.56. In terms of profitability, NUVO's ROE is -0.37%, compared to RPID's ROE of -0.95%. Regarding short-term risk, NUVO is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for NUVO.Check RPID's competition here